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Laboratory characteristics of a cohort of 
patients with early rheumatoid arthritis
Licia Maria Henrique da Mota1, Leopoldo Luiz dos Santos Neto2, 
Rufus Burlingame3, Henri A Ménard4, Ieda Maria Magalhães Laurindo5
ABSTRACT
Introduction/Objective: To characterize a population of patients with early rheumatoid arthritis (RA) according to 
laboratory aspects, comparing it with other similar cohorts. Methods: Data presented are part of a prospective incident 
cohort study that evaluated 65 patients with early RA, followed for 36 months from the diagnosis at Early Rheumatoid 
Arthritis Clinic of Hospital Universitário de Brasília (HUB). We recorded demographics, clinical, and laboratory data 
relevant to the cohort initial assessment, including red blood cells, evidence of inflammatory activity, and presence of 
autoantibodies (rheumatoid factor (RF)), cyclic citrullinated peptide antibodies (anti-CCP), and antivimentin citrullinated 
(anti-Sa). Results: There was a preponderance of female (86%) with mean age of 45.6 years. Twelve patients (18.46%) 
had laboratory diagnosis of anemia (hemoglobin < 12 g / dL). Erythrocyte sedimentation rate (ESR) and C-reactive 
protein (CRP) were above the reference value for 51 (78.46%) and 46 (70.76%) patients, respectively. Thirty-two pa-
tients (49.23%) were positive for at least one of the RF isotypes, and 28 patients (43.07%) were positive for IgA RF, 19 
(29.23%) for IgG, and 32 ( 49.23%) for IgM RF, respectively; 34 patients (52.30%) were positive for at least one of the 
techniques used in investigation of anti-CCP (CCP2, or CCP3, or CCP3.1), while 9 (13,85%) were positive for anti-Sa. 
Conclusions: The laboratory characteristics of patients enrolled in this Brazilian cohort are similar in many respects to 
those of North-American, European, and Latin-American cohorts previously published.
Keywords: early rheumatoid arthritis, RF, anti-CCP, anti-Sa, cohort, Brazilian population, early arthritis.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic condition with 
irreversible potential for bone and cartilage damage, which, 
despite recent advances regarding its management, remains 
costly for the affected individual and society.1 
Although it is well known that RA has varying characteristics 
according to the population affected, most available 
information, especially with regard to early RA, comes from 
Europe and the United States, with few studies in Latin 
American populations.2-4
There is no Brazilian cohort study involving patients 
with early RA. Thus, the laboratory features of early RA in 
the Brazilian population are unknown, as well as if there is 
difference from other populations previously studied.
The aim of this study was to characterize a population of 
patients with early RA according to laboratory tests, including 
hemoglobin levels; evidence of inflammatory activity by 
erythrocyte sedimentation rate (ESR) and C-reactive protein 
(CRP); presence of autoantibody rheumatoid factor (RF), 
cyclic citrullinated peptide (CCP) antibody, and antivimentin 
citrullinated (anti-Sa).
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PATIENTS AND METHODS
Data presented are part of a prospective incident cohort study, 
which evaluated consecutive patients with early RA diagnosis, 
regularly followed-up for 36 months since diagnosis performed 
at Early Rheumatoid Arthritis Clinic of Hospital Universitário 
de Brasília (HUB).
Early RA was defined as the occurrence of joint symptoms 
compatible with the disease (pain and swelling joints of 
inflammatory pattern, with or without morning stiffness or 
other manifestations suggestive of inflammatory joint disease, 
as assessed by a single observer) and lasting more than six 
weeks and less than 12 months, regardless of meeting the 
qualifying criteria of the American College of Rheumatology 
(ACR).5
We recorded demographic and clinical data, as well as 
laboratory parameters relevant to the cohort initial assessment. 
Complete blood count and evidence of inflammatory activity 
(ESR and CRP) were performed at the Laboratory of Clinical 
Pathology of Hospital Universitário de Brasília.
Measurement of RF (IgG, IgM and IgA) was performed 
at INOVA Diagnostics, Inc., San Diego, California, United 
States, using “Quanta LiteTM RF IgA ELISA”, “Quanta LiteTM 
RF IgG ELISA”, and “Quanta LiteTM RF IgM ELISA” assays 
(Inova Diagnostics, CA, USA), according to manufacturer 
protocol. We considered as cutoff points for positivity values 
higher than 15 IU/mL (IgM and IgA) and 20 UI/mL (FR IgG).
Anti-CCP was studied using “Quanta LiteTM CCP IgG 
ELISA”, “Quanta LiteTM CCP3 IgG ELISA” and “Quanta 
LiteTM CCP3.1 IgG/IgA ELISA” (Inova Diagnostics CA, 
USA), according to manufacturer protocol. The serum of each 
patient was initially diluted at 1:100 in sample diluent. If the 
result of a sample had an optical density greater than 2.5, it 
was retested with dilutions at 1:500 and 1:2500, and the unit 
resulting value multiplied by the dilution factor. Results were 
expressed in units (U), with < 20 U considered negative, 20-
39 U weak positive, 40-59 U moderate positive, and ≥ 60 U 
strong positive, for all tests.
The test for detection of anti-Sa was performed on the 
original plates developed by McGill University Autoimmune 
Research Laboratory.6 The results were calculated and 
expressed in units: < 20 U negative, 21-79 U doubtful, and ≥ 
80 U positive. The samples were processed for this purpose 
in the Division of Rheumatology, McGill University Health 
Center, Quebec, Canada.
Patients received standard treatment regimen used in the 
service, including the traditional disease modifying anti-
rheumatic drugs (DMARDs) or biological response modifier 
therapy, according to necessity. 
Descriptive statistics was performed for all assessed 
variables. To detect differences between two means, the 
Student’s t-test or paired t-test for samples of normal 
distribution was used, considering the average values and 
standard deviation.
For cases in which normality was rejected, we applied the 
nonparametric Wilcoxon test or Mann-Whitney test taking into 
account the median value and the interquartile range. 
The study was approved by the Research Ethics Committee 
of Faculdade de Medicina da Universidade de Brasília (CEP 
FM-UnB). Project registration: CEP-FM 028/2007.
RESULTS
Characteristics of study population
Initially, we evaluated 65 patients diagnosed with early RA, 
mean age of 45-64 years (± 14-51), ranging from 26 to 71 years. 
There was a predominance of female (56 patients, 86.15%) 
and white ethnic group (31 patients, 47.69%). The duration of 
joint symptoms before diagnosis was on average 32 weeks (± 
15.41). Although the ACR criteria have not been considered 
for early RA definition in this study, all 65 patients met at least 
four criteria in the first assessment. Table 1 summarizes these 
population demographic and clinical characteristics.
Red cell counts
In the initial evaluation, the mean hemoglobin value of 65 
patients was 12.73 g/dL (± 1.06). Twelve patients (18.46%) 
had laboratory diagnosis of anemia (hemoglobin < 12 g/dL), 
with mean hemoglobin value of 10.91 g/dL (± 1.21).
Evidence of inflammatory activity
As for VHS, 51 patients (78.46%) had values above those of 
reference test, with the average value of 40.43 mm in the first 
hour (± 16.97). The level of CRP showed higher values than 
the reference test (1.0 mg/dL) in 46 patients (70.76%), and the 
average value found was 2.46 mg/dL (± 1.72).
Autoantibodies
Rheumatoid factor
In the first assessment, among the 65 patients, 32 subjects 
(49.23%) were positive for at least one of the RF isotypes, and 
28 patients (43.07%) were positive for RF IgA, 19 (29.23%) 
for IgG, and 32 (49.23%) for IgM RF, respectively. Among 
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those with positive serology for RF, the mean titers of IgA at 
baseline were 76 IU/dL (± 56.17), RF IgG 71 IU/mL (± 51.21), 
and RF IgM 105 IU/mL (± 73.13). 
Twenty-eight patients (43.07% of the total sample and 
87.50% of those positive for at least one of the RF serotypes) 
were positive for more than one serotype. Seventeen patients 
(26.15% of the total sample and 53.12% of those positive for 
at least one of the RF serotypes) were positive for all three RF 
serotypes. Two patients (3.07% of the total sample and 6.25% 
were positive for at least one of the RF serotypes) were positive 
only for IgA RF, and six patients (9.23% of the total sample and 
18.75 % of those positive for at least one of the RF serotypes) 
were positive only for IgM and negative for the other serotypes. 
No patient tested positive only for IgG. Five patients (7.69% 
of total sample and 15.62% of those positive for at least one 
RF serotype) were positive for RF IgA, IgM and negative for 
IgG, while two (3.07% of the total sample and 6.25% of those 
positive for at least one of the RF serotypes) were positive for 
IgG and IgM but negative for IgA RF. No patient was positive 
for IgA and IgG or negative for IgM.
Cyclic citrullinated peptide antibodies (anti-CCP)
As for anti-CCP antibodies, 34 patients (52.30% of the total) were 
positive for at least one of the techniques used in screening (CCP2, 
CCP3, or CCP3.1). With the use of ELISA 2 (CCP2) technique, 
33 patients (50.77% of the total population tested) were negative, 
five (7.69%) were weak positive, and 27 (41.54%) were strong 
positive. With ELISA 3 (CCP3) technique, 30 patients (46.15%) 
were negative, five (7.69%) were weak positive, two (3.08%) 
were moderate positive, and 28 (43.08%) were strong positive. 
With ELISA 3.1 (CCP3.1) technique, 31 patients (47.69%) were 
negative, two (3.08%) were weak positive, three (4.62%) were 
moderate positive, and 29 (44.62%) were strong positive.
Among those with positive serology for anti-CCP, the 
average values obtained by CCP2 technique at baseline were 
568 IU/dL (± 833.28); by CCP3, 1,148 IU/mL (± 1,584.15); and 
by CCP3.1, 1,272 IU/mL (± 1,721.97). Titles obtained by the 
third generation techniques were not significantly higher than 
those obtained by the second generation technique (P > 0.05).
Thirty-two patients (49.23% of the total population and 
94.11% of those with positive results for at least one of the 
techniques) were positive for anti-CCP in more than one 
technique, while 29 patients (44.61% of total population and 
85.29% of those positive for at least one of the techniques) 
were positive for all three techniques.
Three patients (4.62% of the total population and 8.82% 
among the positives) were positive for anti-CCP3 and CCP3.1 
and negative for anti-CCP2, and one patient (1.53% of total 
population and 2.94% among positives) was positive for CCP3 
and negative for CCP2 and CCP3.1 (in all cases, positive results 
were weak positive). Two patients (3.08% of total population 
and 5.88% of the total number of positives) were positive for 
anti-CCP 3.1 and CCP 2 and negative for CCP3 (in both cases 
the result by CCP3.1 technique was weak positive). There was 
no statistical difference between positivity for anti-CCP analyzed 
by different techniques – CCP 2, CCP 3, and CCP 3.1 (P > 0.05).
Antivimentin citrullinated (anti-Sa)
At baseline assessment, of the 65 patients evaluated, 52 (80%) 
were anti-Sa negative, four (6.15%) had an uncertain outcome, 
and nine (13.85%) were positive. Among those with anti-Sa 
positive serology, the mean values obtained at baseline was 370.2 
IU/dL (± 263.80). Table 2 summarizes the profile of positivity 
for RF, anti-CCP, and anti-Sa in 65 patients initially evaluated.
DISCUSSION
The interaction between multiethnic origins, colonial heritage, 
and immigration patterns in Latin America resulted in rather 
complex demographic characteristics and in a highly mixed 
population, varying between different countries in the region, 
with a wide variability of gene expression. 2-4
Table 1
Patients with early rheumatoid arthritis assessed at 
Hospital Universitário de Brasília according to their 
general characteristics (baseline assessment, n: 65)
Characteristics n (±) or n (%)
Age (years) 45.64 (± 14.51)
Sex Male 9 (13.80%)
Female 56 (86.15%)





Education (years) 8.3 (± 4.95)
Duration of disease (weeks) 32 (± 15.41)
Current or previous smoking 7 (10.76%)
DAS 28 6.79 (± 1.11)
HAQ 1.87 (± 0.81)
Radiographic erosion 31 (47.69%)
Variables are represented in mean absolute value (± standard deviation) or n (%). 
DAS 28: disease activity index; HAQ: Health Assessment Questionnaire.
Mota et al.
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Data on incidence, prevalence, and characteristics of 
RA in populations of Latin American countries are scarce.7 
In analyzing the results of studies on AR performed in 
developing countries, one should bear in mind that the disease 
characteristics can be affected by socioeconomic, demographic, 
and health systems of these countries.8
The characteristics of patients in our cohort were compared 
with data from other cohorts, American and European, and 
with preliminary information from GLADAR,9 prospective, 
multicenter observational cohort study that evaluated  1,059 
patients with early RA, allocated in 46 centers of 14 Latin 
American countries.10,11 The Rheumatology Service of HUB/
UnB participated in the GLADAR study with 30 patients other 
than those evaluated in this study.
Hemocytometer
Anemia is a relatively frequent extra-articular manifestation 
in early RA (6-25%), and seems to correlate with worse 
joint prognosis,12 functional disability, need for orthopedic 
intervention,13 and mortality.14 Decreased RBC count is more 
frequent among male, smokers, patients with high levels of 
evidence of inflammatory activity, presence of RF,  ANA and 
shared epitope.14
Nikolaisen et al.15 investigated the prevalence of anemia in 
a cohort of 111 consecutive patients with early RA during 74 
months of follow-up and found reduced levels of hemoglobin 
in 25% of patients during the first year of follow-up. In this 
study, the presence of anemia was associated with higher 
levels of ESR, CRP, and IL-6, but not the more aggressive 
joint disease or mortality.
Evidence of inflammatory activity
More than two thirds of patients in our cohort showed increased 
evidence of inflammatory activity (ESR and CRP) tested at 
baseline.
The evidence of inflammatory activity at baseline does 
not seem to discriminate RA from other early arthritis, and 
do not predict persistent disease (erosive).16-18 Tunn and 
Bacon reported that, among patients of an early RA clinic 
who developed persistent arthritis, levels significantly higher 
of ESR was found. However, in this study, ESR had low 




At baseline evaluation, about 50% of patients in our cohort 
were positive for at least one of the RF serotypes, a percentage 
lower than that reported for GLADAR cohort (76%).20 It is 
important to highlight the different methods employed for RF 
research by GLADAR (Waaler-Rose, nephelometry, ELISA). 
RF positivity in our study was similar to other studies that 
used ELISA,21-22 including the results of Nishimura et al. 
meta-analysis.
In our study, we chose to research RF isotypes IgA, IgG, 
and IgM. The validity of the RF isotypes research in the 
assessment of early RA remains questionable. For example, 
the existence of correlation between titers of different isotypes 
of RF and the diagnosis of RA is not defined, as well as the 
relation between the presence of some specific serotype (or 
more than one) and a worst radiologic prognostic, or the 
behavior of different RF isotypes over time.23
In our population, we observed IgM RF in 50%, IgA in 
42% and IgG in 30% of patients diagnosed with RA and 
symptoms lasting less than 12 months, similar rates to those 
Table 2
Baseline serum characteristics of patients 
with early rheumatoid arthritis (n: 65)
Autoantibody n (%)/title (IU/dL) - mean (± SD)
RFs (any isotype) 32 (49.23%)
RF  IgM 32 (49.23%)/ 105 (± 73.13)
RF IgG 19 (29.23%) / 71 (± 51.21)
RF IGA 28 (43.07%) / 76 (± 56.17)
RF IgM+ IgG + IgA+ 17 (26.15%)
RF IgA+ IgM+IgG- 5 (7.69%)
RF IgM + IgG- IgA- 6 (9.23%)
RF IgA +IgM- IgG- 2 (3.07%)
RF IgM+ IgG+ IgA - 2 (3.07%)
Anti-CCP (any technique) 34 (52.3%)
CCP2 32 (49.23%) / 568 (± 833.28) 
CCP3 35 (53.85%) / 1,148 (± 1,584.15)
CCP3.1 34 (52.31%) / 1,272 UI/mL(± 1,721.97)
CCP2 + CCP3 + CCP3.1 + 29 (44.61%)
CCP2 - CCP3 + CCP3.1 + 3 (4.62%)
CCP2 - CCP3 + CCP3.1 - 1 (1.53%)
CCP2 - CCP3 - CCP3.1 + 2 (3.08%)
Anti-Sa 9 (13.85%) / 370.2 (± 263.8)
Variables are represented in mean absolute value (± standard deviation) or n (%). 
RF: rheumatoid factor; CCP: cyclic citrullinated peptide antibodies; 
anti-Sa: antivimentin citrullinated antibodies.
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referred in other works, such as the work by Vittecoq et al., 24 
which described the presence of IgM RF in 51%, IgA RF in 
36%, and IgG RF in 32% of patients diagnosed with RA with 
less than two years duration.
IgM RF is a useful marker to discriminate patients with 
polyarthritis that will evolve or not to RA.25-30 In contrast, the 
diagnostic properties of RF IgA and IgG are questionable.30-32 
In our study, the research of RF serotypes IgA and IgG did not 
increase the frequency of RF positivity and, therefore, does 
not contribute to RA diagnosis.
Some published studies have evaluated, as in our cohort, 
the average titles of different RF serotypes in early RA, and 
our results are similar to those reported by other authors.23,33
Cyclic citrullinated peptide antibodies (anti-CCP)
The percentage of positivity for anti-CCP in our study was 
similar to that reported by several other studies involving 
patients with early RA. Fifty percent of patients in our cohort 
were positive for at least one of the techniques used in the 
assessment (CCP2, CCP3, or CCP3.1), and most were strong 
positive by the all three techniques. In a systematic literature 
review, the combined analysis of publications referring to more 
than 2,000 patients with early undifferentiated arthritis showed 
a 23% prevalence of anti-CCP (ELISA 2nd generation). This 
prevalence increased to 51% in over 1,000 patients who met 
criteria for RA after a mean follow-up of 18 months.34
In our cohort, the prevalence of RF and anti-CCP was 
approximately the same (considering CCP positive for any 
of the three techniques examined), which was similar to 
other studies on the subject-matter.35-36 As reported by several 
authors, CCP2 appears to be as sensitive as – and more specific 
than – IgM RF, but their advantage would be the detection of 
antibodies in approximately 15% of patients with RA who are 
negative for RF. 37-45 Nishimura et al.,23 in their meta-analysis 
of published studies on  accuracy of anti-CCP and RF for RA, 
have concluded that positivity for anti-CCP alone is more 
specific than the isolated positivity for IgM RF in RA diagnosis.
In our cohort, there was no difference between the 
techniques considered for detection of anti-CCP (CCP2, CCP3, 
and CCP3.1), and the prevalence of anti-CCP antibodies was 
almost the same by all three techniques (40%). The difference 
in sensitivity, specificity, and cost-effective among the three 
techniques for detection of anti-CCP is still controversial in 
literature, and studies in different populations are needed.46
In 2005, a third generation of anti-CCP (CCP3) became 
available for laboratory diagnosis of RA. It was reported that 
these tests would recognize additional citrullinated epitopes, 
which would not be identified by the second generation test 
(CCP2), with sensitivity 5% greater than CCP2,  maintaining 
specificity.47 
CCP3 test was evaluated Santiago et al.48 and Wu et al.49 and 
found to be more sensitive than the CCP2 while maintaining 
specificity. Anjos et al.46 reported in a population of 70 patients 
with RA in southern Brazil that both CCP2 and CCP3 showed 
good diagnostic performance, with CCP3 4.3% more sensitive 
than CCP2, while maintaining specificity. However, other 
authors have reported very similar diagnostic performance 
between CCP2 and CCP3 tests.50-51
The CCP3.1 evaluated in our study (INOVA) uses a 
conjugate that detects antibodies IgA, as well as the usual 
IgG antibodies, which in theory would improve the method 
sensitivity, since some patients with RA have IgA antibodies 
against CCP3, in the absence of IgG antibodies.52 Bizzaro et 
al.,53 however, comparing 11 different laboratory techniques 
for CCP detection, noted a slight difference in results 
between CCP2 and CCP3 INOVA (sensitivity 64% and 67%, 
respectively) and no difference between CCP3 and CCP3.1, 
suggesting that the combination of IgA and IgG would not 
improve test performance, similar to what was observed in 
our cohort.
In our cohort, the titles of CCP obtained by three different 
techniques were similar. Titles of CCP2 on average tended to be 
lower than the third generation techniques. We observed high 
values (on average > 500 IU/dL) with the three techniques, 
higher than those reported in publications by Lee et al.54 and 
Papadopoulos et al.,55 two of the few studies on absolute titles 
of anti-CCP  and its correlation with disease progression.
Antivimentin citrullinated (anti-Sa)
Less than 15% of our patients’ cohort presented with anti-Sa 
antibodies in the initial evaluation; this value is less than that 
reported by Boire et al.6 (28% of their cohort of 165 patients 
with early polyarthritis) and Vossenaar et al.56 (40% of 87 sera 
from patients with established RA).
The mean titers of anti-Sa found in our cohort varied from 
200 to 300 IU/dL, values similar to those found by other 
authors,6,57 although there are few publications on the subject.
CONCLUSIONS
Although the demographic and clinical characteristics of 
patients enrolled in this Brazilian cohort differ in several 
aspects from those of North American, European, and Latin 
American cohorts previously published, our laboratory 
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findings, including the initial prevalence of autoantibodies, 
are similar to other populations.
The prevalence of RF and anti-CCP (50%) was similar 
to that reported in other cohorts of early RA. As the initial 
positivity for both autoantibodies was similar in our cohort, 
we infer that, in our specific population, anti-CCP did not 
aggregate value for the diagnosis of RA in its initial phase.
Additionally, there was no difference between the 
techniques considered for detection of anti-CCP (CCP2, CCP3, 
and CCP3.1), suggesting that the third-generation tests did not 
bring contribution to the diagnosis of early RA. Moreover, the 
research of anti-Sa was not useful for diagnosis of early RA, 
compared to RF and anti-CCP.
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